Aurora Launches New Medical Cannabis Product in Australia
Aurora Cannabis Inc. (NASDAQ: ACB) has taken an exciting step in enhancing its medical cannabis offerings with the introduction of IndiMed TEMPO 22. This latest addition is available through MedReleaf Australia, a dedicated subsidiary of Aurora. With a THC potency of 22%, this new product promises to broaden the treatment landscape for healthcare providers and patients alike.
New Cultivars From IndiMed
The launch of IndiMed TEMPO 22 marks an important milestone for Aurora, further establishing their brand as a trusted name in medical cannabis. This move not only reflects the company's dedication to innovation but also its responsiveness to the diverse needs of patients. The two new cultivars being introduced into the Australian market include:
IndiMed TEMPO 22 - Special Varieties
1. Lemon Laser - Sativa, 22% THC, <1% CBD, Dried Cannabis (15g)
2. Pickled Petrol - Indica, 22% THC, <1% CBD, Dried Cannabis (15g)
Commitment to Quality and Innovation
Aurora’s continuous emphasis on quality and expansion of access to medical cannabis reinforces its leadership in the global market. The company aims to ensure that practitioners and their patients receive consistent and high-quality products.
According to Andre Jerome, Executive Vice President of Global Business Development at Aurora, this expansion not only fulfills patient needs but also highlights the company’s innovative spirit. "Expanding our portfolio in the value segment underscores our mission to provide accessible, high-quality medical cannabis options for diverse patient needs," he stated.
The Role of MedReleaf Australia
As a wholly-owned subsidiary of Aurora, MedReleaf Australia is dedicated to meeting the stringent TGA-GMP standards for medicinal products. This commitment to quality assures healthcare professionals and patients that they are receiving reliable and effective treatments.
About Aurora Cannabis Inc.
Headquartered in Edmonton, Alberta, Aurora Cannabis is recognized as a leading global provider of medical and consumer cannabis products. With operations spanning across Canada, Europe, Australia, and New Zealand, Aurora is committed to enhancing the lives of people through the benefits of cannabis. Their diverse product array includes various medical cannabis brands such as MedReleaf, CanniMed, and the recently highlighted IndiMed.
Investor Relations and Contact Information
Aurora’s common shares are publicly traded on NASDAQ and TSX under the ticker symbol "ACB." For further inquiries related to media or investor relations, Aurora provides dedicated contact points:
Media Contact: Michelle Lefler | VP, Communications & PR
Investor Contact: ICR, Inc.
Frequently Asked Questions
What is IndiMed TEMPO 22?
IndiMed TEMPO 22 is a new medical cannabis product from Aurora Cannabis featuring a THC potency of 22%, aimed at expanding treatment options for patients.
Which cultivars are part of the IndiMed TEMPO 22 launch?
The launch includes Lemon Laser (Sativa) and Pickled Petrol (Indica), both with the specified THC level.
How does Aurora ensure the quality of its products?
Aurora operates under strict TGA-GMP standards with a commitment to delivering high-quality and reliable medical cannabis to patients.
What markets does Aurora operate in?
Aurora operates globally, providing cannabis products across Canada, Europe, Australia, and New Zealand.
How can health professionals contact MedReleaf Australia?
Healthcare professionals can reach out to MedReleaf Australia's clinical support team for assistance regarding their offerings.
